If you have been reading about Thymalfasin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
=== Clement Cowan === Clement Cowan (Derek Riddell) is a VP at Pierpoint's CPS desk, and Robert's manager during his internship. Clement covers only one account: Kaspar Zenden, a Dutch investor he has known for 20 years. Though initially distant and aloof, Clement forms a kinship with Robert over their shared working-class origins. He reveals to him that he is actually Scottish, but hides his background and accent to fit in with Pierpoint's elite. Robert also learns that Clement is heroin addict. Clement is eventually fired at the end of series 1 during a Pierpoint reorg. In series 2, Robert learns that Clement died and left him half a million pounds in his will, which Robert uses to buy himself a house in series 3.
=== Venom system morphology === Little is known about the venom and the venom apparatus of centipedes. Studies on venom gland described it as the cuticle and epidermis being turned inside out. The venom gland consists of many epithelial secretory units, each with its own excretory system that is shaped like valves. Centipedes of the order Scolopendromorpha have interspersed radial striated muscles between the secretory units, where one end connects to the lumen of the venom gland and the other end connects to peripheral muscles. These muscles may be used for the contraction and constriction of anthe gland during venom ejection. The venom glands of Scolopendridae species are elongated cylindrical shape, with the lumen spanning almost the entire length of the gland. The long span of the lumen likely allows greater control over the secretion of different venom components. The venom glands span along the outer curvature of trochanteroprefemur of each forcipule.
== Methods in development == DNA sequencing methods currently under development include reading the sequence as a DNA strand transits through nanopores (a method that is now commercial but subsequent generations such as solid-state nanopores are still in development), and microscopy-based techniques, such as atomic force microscopy or transmission electron microscopy that are used to identify the positions of individual nucleotides within long DNA fragments (>5,000 bp) by nucleotide labeling with heavier elements (e.g., halogens) for visual detection and recording. Third generation technologies aim to increase throughput and decrease the time to result and cost by eliminating the need for excessive reagents and harnessing the processivity of DNA polymerase.
=== White's Fort === In 1786, White moved to the future site of Knoxville, where he and fellow explorer James Connor built what became known as White's Fort. The site straddled a hill that was bounded by the river on the south, creeks (First Creek and Second Creek) on the east and west, and a swampy declivity on the north. The fort, which originally stood along modern State Street, consisted of four heavily timbered cabins connected by an 8-foot (2.4 m) palisade, enclosing one-quarter acre of ground. White also erected a mill for grinding grain on nearby First Creek. White's Fort represented the western extreme of the so-called State of Franklin, which Tennessee settlers organized in 1784 after North Carolina reneged on its plans to cede its western territory to the federal government. James White supported the State of Franklin, and served as its Speaker of the Senate in 1786. The federal government never recognized the State of Franklin, however, and by 1789, its supporters once again pledged allegiance to North Carolina. In 1789, White, William Blount, and former State of Franklin leader John Sevier, now members of the North Carolina state legislature, helped convince the state to ratify the United States Constitution. Following ratification, North Carolina ceded control of its Tennessee territory to the federal government. In May 1790, the United States created the Southwest Territory, which included Tennessee, and President George Washington appointed Blount the territory's governor.
Sources: en.wikipedia.org
Cows is a chain of ice cream parlours and cheesemongers with nine locations in Canada and one in the United States. It started in 1983 in Prince Edward Island as an ice cream parlour. Today it is known for its 32 varieties of ice cream, cheddar cheese, and cow-themed merchandise. Sales of Cows ice cream spiked in the summer of 2010, after American television hosts Regis and Kelly showed interest in the chain.
Belize is a country on the north-eastern coast of Central America. It is bordered by Mexico to the north, the Caribbean Sea to the east, and Guatemala to the west and south. It also shares a maritime boundary with Honduras to the southeast. Part of the Caribbean region, Belize is a member of the Caribbean Community (CARICOM) and the Commonwealth Caribbean, the historical British West Indies. The Maya civilization spread into the area of Belize between 1500 BC and 300 AD and flourished until about 1200. European contact began in 1502–1504 when Christopher Columbus sailed along the Gulf of Honduras. European exploration was begun by English settlers in 1638. Spain and Britain both laid claim to the land until the British victory over the Spanish in the Battle of St. George's Caye (1798). It became a British colony in 1840 and a Crown colony in 1862. From then until 1973 it was known as British Honduras. Belize achieved its independence from the United Kingdom on 21 September 1981. It is the only mainland Central American country which is a Commonwealth realm, with King Charles III as its monarch and head of state, represented by a governor-general. Belize's abundance of terrestrial and marine plants and animals and its diversity of ecosystems, including extensive coral reefs, give it a key place in the globally significant Mesoamerican Biological Corridor. It is considered a part of both Central America and the Caribbean. It has an area of 22,970 square kilometres (8,867 sq mi) and a population of 397,483 (2022).
== History == CTS was first described around 1850 but was infrequently diagnosed until findings were publicized by neurologist W. Russell Brain in 1947. People were often diagnosed with acroparesthesia. Clinicians would often ascribe it to "poor circulation" and not pursue it further. Sir James Paget described median nerve compression at the carpal tunnel in two patients after trauma in 1854. The first was due to an injury where a cord had been wrapped around a man's wrist. The second was related to a distal radial fracture. For the first case, Paget performed an amputation of the hand. For the second case, Paget recommended a wrist splint. The first to notice the association between the carpal ligament pathology and median nerve compression appears to have been Pierre Marie and Charles Foix in 1913. They described the results of a postmortem of an 80-year-old man with bilateral carpal tunnel syndrome. They suggested that division of the carpal ligament would be curative in such cases. Putman had previously described a series of 37 patients and suggested a vasomotor origin. The association between the thenar muscle atrophy and compression was noted in 1914. The name "carpal tunnel syndrome" appears to have been coined by Moersch in 1938. Physician George S. Phalen of the Cleveland Clinic drew attention to the pathology of compression as the reason for CTS after working with a group of patients in the 1950s and 1960s.
=== Basicity === Compared to amines, amides are very weak bases. While the conjugate acid of an amine has a pKa of about 9.5, the conjugate acid of an amide has a pKa around −0.5. Therefore, compared to amines, amides do not have acid–base properties that are as noticeable in water. This relative lack of basicity is explained by the withdrawing of electrons from the amine by the carbonyl. On the other hand, amides are much stronger bases than carboxylic acids, esters, aldehydes, and ketones (their conjugate acids' pKas are between −6 and −10). The proton of a primary or secondary amide does not dissociate readily; its pKa is usually well above 15. Conversely, under extremely acidic conditions, the carbonyl oxygen can become protonated with a pKa of roughly −1. It is not only because of the positive charge on the nitrogen but also because of the negative charge on the oxygen gained through resonance.
Tuftsin is a tetrapeptide (Thr-Lys-Pro-Arg, TKPR) located in the Fc-domain of the heavy chain of immunoglobulin G (residues 289-292). It has an immunostimulatory effect. It is named for Tufts University where it was first discovered in 1983.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.